NCT04764201

The Pharmacokinetic Characteristics and Safety Between HIP2001 and HGP2001 in Healthy Volunteers

A Randomized, Open Label, Single Dose, 2-way Crossover Clinical Trial to Evaluate the Pharmacokinetic Characteristics and Safety Between HIP2001 and HGP2001 in Healthy Volunteers

• Status: Completed
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 50 (actual)
• Sponsor: Hanmi Pharmaceutical Company Limited · Industry
• Sex: All
• Age: 19 Years – 45 Years
• Healthy volunteers: Accepted

Summary

The purpose of this study is to evaluate the pharmacokinetic characteristics and safety between HIP2001 and HGP2001 in healthy volunteers.

Conditions

• Atrial Fibrillation

Interventions

Type	Name	Description
DRUG	HIP2001	Test drug
DRUG	HGP2001	Reference drug

Timeline

• Start date: 2021-01-16
• Primary completion: 2021-02-26
• Completion: 2021-03-08
• First posted: 2021-02-21
• Last updated: 2021-04-01

Locations

1 site across 1 country: South Korea